Recent discrepancies concerning the role of AR have been noted in various TNBC basic and clinical studies and both AR agonist and AR antagonist clinical trials have been designed for the treatment of TNBC and ER+ breast cancers [41–43]. The gene discussed is AR; the disease is breast carcinoma.